Nxera Pharma
Manufacturing · Japan · 350 Employees
View Company Info for Free
About
Headquarters
Pmo Hanzomon 11TH Fl 2-1, Tokyo, Tokyo, 102-008...Phone Number
+81 352103290Website
nxera.lifeRevenue
$103.5 MillionIndustry
Who is Nxera Pharma
Nxera Pharma Co. Ltd is a company that operates in the Pharmaceuticals industry. It employs 250to499 people and has 100MMto250M of revenue. The com pany is headquartered in Tokyo, Tokyo, Japan.Read more
Popular SearchesNxera Pharma Co. LtdNxera Pharma Co LtdNxera PharmaNxera Pharma CoNxera Pharma Korea Co LtdSIC Code 28,283NAICS Code 32,325Show more
Nxera Pharma Org Chart
Is Nxera Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Nxera Pharma recently announced quarterly report
Nxera Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if Nxera Pharma has recently received funding, and reach out quickly before it becomes old news!
Click to see if Nxera Pharma had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Nxera Pharma is spiking on competitors!
Funding: Get notified immidiatlly once Nxera Pharma has new funding data
Product Launch: Get notified when Nxera Pharma launches new products
Congratulate Masked Content for being promoted to Masked Content at Nxera Pharma
Recommended Actions
Find VP level buyers at Nxera Pharma
Find more new buyers
Nxera Pharma Employee Growth Rate
View Nxera Pharma’s full employee growth data
Percentage of growth
1st year Mask
2nd year Mask
Nxera Pharma Tech Stack
A closer look at the technologies used by Nxera Pharma
See more technologies
Most Recent Scoops
Jul 12 2024
Open Position
Jul 12 2024
Open Position
Nxera Pharma News & Media
Nxera’s Partner Cancer Research UK to Present on Phase 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732 at ESMO
Tokyo, Japan and Cambridge and London, UK, 13 September 2024 – Nxera Pharma (TSE: 4565, “Nxera”) and Cancer Research UK announce an upcoming presentation on the ongoing Phase 1/2a clinical trial (NCT05944237) of Nxera’s immunotherapy drug HTL0039732 (also known as NXE0039732) at the European Society for Medical Oncology Congress (ESMO) 2024, taking place on 13–17 September in Barcelona, Spain.
Nxera Pharma’s Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
Tokyo, Japan and Cambridge, UK, 11 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – notes the announcement by Centessa Pharmaceuticals on 10 September 2024 reporting positive interim clinical data from its Phase 1 clinical trial with ORX750 in acutely sleep-deprived healthy volunteers. The full announcement from Centessa can be found by clicking here.Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
Tokyo, Japan and Cambridge, UK, 2 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it will receive a US$35 million payment from Neurocrine Biosciences (‘Neurocrine’), triggered by the successful completion of the Phase 2 trial with NBI-1117568 (NBI-‘568) in adults with schizophrenia, as announced on 28 August 2024. Receipt of the US$35 million payment will be recognized asNxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
Tokyo, Japan and Cambridge, UK, 28 August 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – notes the announcement by its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX) that NBI-1117568 (NBI-‘568) has delivered positive topline results from its Phase 2 clinical study in adults with schizophrenia. NBI-’568 is the first investigational, oral, muscarinic M4 selective agonist in development for the treatment ofNxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2024
Tokyo, Japan and Cambridge, UK, 9 August 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2024. The full report can be found here.
Read more news
Frequently Asked Questions Regarding Nxera Pharma
Nxera Pharma Co. Ltd is a company that operates in the Pharmaceuticals industry. It employs 250to499 people and has 100MMto250M of revenue. The company is headquartered in Tokyo, Tokyo, Japan.... Read More
